Harvest Portfolios Group Inc. Has $60.47 Million Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

Harvest Portfolios Group Inc. raised its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 8.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 107,547 shares of the biopharmaceutical company’s stock after buying an additional 8,547 shares during the quarter. Regeneron Pharmaceuticals comprises 1.1% of Harvest Portfolios Group Inc.’s investment portfolio, making the stock its 27th largest holding. Harvest Portfolios Group Inc.’s holdings in Regeneron Pharmaceuticals were worth $60,470,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the business. Osaic Holdings Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 55.2% in the second quarter. Osaic Holdings Inc. now owns 17,068 shares of the biopharmaceutical company’s stock valued at $9,607,000 after buying an additional 6,073 shares during the period. PGGM Investments raised its holdings in Regeneron Pharmaceuticals by 9.7% in the 3rd quarter. PGGM Investments now owns 92,584 shares of the biopharmaceutical company’s stock valued at $52,057,000 after acquiring an additional 8,187 shares in the last quarter. Robeco Institutional Asset Management B.V. lifted its position in shares of Regeneron Pharmaceuticals by 153.4% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 120,884 shares of the biopharmaceutical company’s stock worth $67,969,000 after acquiring an additional 73,176 shares during the period. Rakuten Investment Management Inc. acquired a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter worth approximately $33,121,000. Finally, Sound Shore Management Inc CT bought a new stake in shares of Regeneron Pharmaceuticals during the third quarter valued at approximately $64,677,000. 83.31% of the stock is owned by institutional investors.

Key Headlines Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: FDA expanded Dupixent’s label — the U.S. approved Dupixent (dupilumab) for allergic fungal rhinosinusitis in patients aged 6 and older, widening the drug’s approved uses and pediatric market potential. Read More.
• Positive Sentiment: EU recommendation for pediatric CSU approval — the EMA recommended Dupixent for chronic spontaneous urticaria in children aged 2–11, which would make Dupixent the first targeted EU therapy for that age group and further supports franchise growth alongside Sanofi. Read More.
• Positive Sentiment: Analyst/market upgrades — Wall Street Zen raised REGN to a Buy rating, reflecting renewed analyst optimism that can drive additional demand for the shares. Read More.
• Positive Sentiment: Dupixent remains a growth engine — coverage notes Dupixent sales grew strongly (year‑over‑year growth in Q4), reinforcing expectations that REGN’s near‑term revenue and margins will keep improving. Read More.
• Positive Sentiment: Institutional interest in gene-therapy/biotech exposure — hedge‑fund lists and roundups continue to single out Regeneron as a top gene‑therapy/biotech pick, supporting longer‑term investor appetite. Read More.
• Neutral Sentiment: Relative performance context — some commentary notes REGN has lagged the Nasdaq over the past year even as analysts remain bullish; this frames the rally as partly a catch‑up rather than an outright re‑rating. Read More.

Analyst Upgrades and Downgrades

REGN has been the subject of several research reports. Zacks Research cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 6th. HSBC upgraded shares of Regeneron Pharmaceuticals to a “strong-buy” rating in a research report on Monday, November 24th. Scotiabank increased their price target on shares of Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the stock a “sector perform” rating in a research report on Monday, November 24th. BMO Capital Markets lifted their price objective on Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the company an “outperform” rating in a report on Thursday, December 4th. Finally, Truist Financial dropped their target price on Regeneron Pharmaceuticals from $820.00 to $818.00 and set a “buy” rating for the company in a report on Monday, February 2nd. Two analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $793.81.

Insider Activity at Regeneron Pharmaceuticals

In other news, Director Huda Y. Zoghbi sold 1,638 shares of the stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the sale, the director directly owned 1,703 shares of the company’s stock, valued at $1,330,604.99. This represents a 49.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Bonnie L. Bassler sold 1,500 shares of the company’s stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total value of $1,200,000.00. Following the transaction, the director directly owned 1,703 shares in the company, valued at approximately $1,362,400. This represents a 46.83% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 5,274 shares of company stock worth $4,142,738 in the last quarter. Insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $781.67 on Friday. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $821.11. The company has a 50 day moving average of $771.59 and a 200-day moving average of $680.78. The company has a current ratio of 4.13, a quick ratio of 3.39 and a debt-to-equity ratio of 0.09. The firm has a market cap of $82.64 billion, a price-to-earnings ratio of 18.81, a PEG ratio of 2.07 and a beta of 0.40.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, beating analysts’ consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The firm had revenue of $3.88 billion during the quarter, compared to analysts’ expectations of $3.76 billion. During the same period last year, the firm posted $12.07 EPS. The business’s revenue was up 2.5% on a year-over-year basis. On average, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 5th. Investors of record on Friday, February 20th will be given a dividend of $0.94 per share. This is a positive change from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. The ex-dividend date is Friday, February 20th. This represents a $3.76 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 9.05%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.